他汀类药物启用与遗传易感老年人阿尔茨海默病及认知下降风险的关系
这项基于美国芝加哥4个城市社区4807名参与者的纵向队列研究发现,他汀类药物启用与阿尔茨海默病痴呆风险降低相关(HR 0.81,95%CI 0.70-0.94),且该关联在携带APOE ε4等位基因者中更显著(HR 0.60,95%CI 0.49-0.74),不携带者中无显著关联。
要点
- 他汀启用与阿尔茨海默病风险降低相关,尤其在APOE ε4携带者中更明显。
- APOE ε4携带者启用他汀后全局认知和情景记忆年下降速度更慢。
- 不携带APOE ε4者中他汀启用与认知下降无显著关联。
核心结论
- 研究提示他汀类药物可能与APOE ε4等位基因携带者阿尔茨海默病发病风险降低相关,他汀治疗的获益需在随机临床试验中进一步考量,尤其在APOE ε4携带者中。
研究设计与样本
- 基于人群的纵向队列研究,在美国伊利诺伊州芝加哥4个城市社区进行,纳入4807名参与者,他汀启用基于家庭评估时对药物的检查确定。
主要发现
- 参与者平均年龄72岁,63%为女性,61%为非西班牙裔黑人,研究期间1470名(31%)参与者报告启用他汀。
- 在协变量调整的竞争风险模型中,与未使用者相比,他汀启用与临床阿尔茨海默病发病风险降低相关(HR 0.81,95%CI 0.70-0.94)。
- 该关联在APOE ε4等位基因携带者中(HR 0.60,95%CI 0.49-0.74)与不携带者中(HR 0.96,95%CI 0.82-1.12)存在统计学显著差异(交互作用P=0.015)。
- APOE ε4携带者启用他汀后全局认知年下降(β=0.021,95%CI 0.007-0.034)和情景记忆年下降(β=0.020,95%CI 0.007-0.033)也明显更慢;不携带APOE ε4者中他汀启用与认知下降的关联不显著。
关键数值与推荐
- 阿尔茨海默病临床诊断采用NINCDS-ADRDA标准。
- 全局认知的纵向测量包括情景记忆、知觉速度和简易精神状态检查测试。
- 本研究提供II级证据:在65岁及以上人群中,他汀启用与阿尔茨海默病风险降低相关,尤其在存在APOE ε4等位基因时。
临床怎么用
- 作者认为他汀治疗的获益需在随机临床试验中进一步考量,尤其在APOE ε4等位基因携带者中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The association of statin initiation with incident Alzheimer disease (AD) dementia and cognitive decline by the APOE ε4 allele is unknown. Our objective was to examine whether the association of statin initiation with incident AD dementia and cognitive decline differs by the APOE ε4 allele. METHODS: This population-based longitudinal cohort study was conducted in 4 urban communities in Chicago, IL, United States, consisting of 4,807 participants. Statin initiation is based on the inspection of medications during home assessments. Clinical diagnosis for incident AD used the NINCDS-ADRDA criteria, and longitudinal measurements of global cognition consisted of episodic memory, perceptual speed, and the Mini-Mental State Examination tests. RESULTS: The study participants had a mean age of 72 years, consisting of 63% female individuals and 61% non-Hispanic Black individuals. During the study period, 1,470 (31%) participants reported statin initiation. In a covariate-adjusted competing risk model, statin initiation was associated with a reduced risk of incident clinical AD [hazard ratio (HR) 0.81 (95% CI 0.70-0.94)] compared with nonusers. This association was statistically significantly lower (p interaction = 0.015) among participants with the APOE ε4 allele [HR 0.60 (95% CI 0.49-0.74)] compared with those without the APOE ε4 allele [HR 0.96 (95% CI 0.82-1.12)]. The annual decline in global cognition (β = 0.021, 95% CI 0.007-0.034) and episodic memory (β = 0.020, 95% CI 0.007-0.033) was also substantially slower among participants with the APOE ε4 allele after statin initiation compared with nonusers. However, the association of statin initiation with cognitive decline was not significant among those without the APOE ε4 allele. DISCUSSION: Our findings suggest that statins might be associated with a lower risk of incident AD among individuals with the APOE ε4 allele. The benefits of statin therapy need further consideration in randomized clinical trials, especially among those with the APOE ε4 allele. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that among those aged 65 years or older, statin initiation was associated with a reduced risk of Alzheimer disease, especially in the presence of an APOE-e4 allele.
引用
- Rajan KB, Mcaninch EA, Wilson RS, et al. Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults. Neurology. 2024. PMID: 38447103. doi:10.1212/WNL.0000000000209168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。